Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LifeWithoutInsulin

Financiado

Cerrado

Compositions for use in the treatment of insulin deficiency conditions

Tens of millions suffer from insulin deficiency (ID); a condition caused by pancreatic β-cell loss. If untreated, ID is a lethal catabolic disease characterized by hyperglycemia. Thus, the focus of ID research and drug development... ver más

30/11/2021

UNIGE

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITE DE GENEVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-11-30

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIGE

150.00K€ | Lider

TUBOPLAST HISPANIA

426.49K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

LightCure LightCure - Light for double specificity and efficacy withou... 8M€ Cerrado

RYC2020-029929-I A MULTICELLULAR APPROACH FOR THE STUDY OF DIABETIC RETINOPAT... 324K€ Cerrado

DIAPREPP DIAbetes type 1 PRediction Early Pathogenesis and Preventio... 8M€ Cerrado

BETACURE Personalized diagnosis and treatment of hyperinsulinemic hyp... 8M€ Cerrado

FJCI-2017-31716 Enfermedades metabólicas (Diabetes y complicaciones clínicas... 50K€ Cerrado

BES-2013-063982 LA INHIBICION DE LA PROTEINA TIROSINA FOSFATASA 1B EN EL TRA... 84K€ Cerrado

Duración del proyecto: 19 meses Fecha Inicio: 2020-04-02
Fecha Fin: 2021-11-30

Líder del proyecto

UNIVERSITE DE GENEVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Tens of millions suffer from insulin deficiency (ID); a condition caused by pancreatic β-cell loss. If untreated, ID is a lethal catabolic disease characterized by hyperglycemia. Thus, the focus of ID research and drug development has been mainly on improving strategies to lower hyperglycemia without causing life-threatening hypoglycemia. However, in addition to increased circulating glucose level β-cell loss leads to several other defects, some of which (e.g. severe hyperketonemia and ketoacidosis) are life-threatening. Therefore, it is important to develop strategies that in addition to improve hyperglycemia can also rescue the other defects (e.g. increased ketogenesis) caused by ID. For example, we have recently published results underscoring the importance of ameliorating hyperglycemia and the other defects. Indeed, our data indicate that despite the presence of slightly improved hyperglycemia a normalization of hyperketonemia and hypertriglyceridemia is associated with a significant extension in lifespan of mice with β-cell loss (https://www.nature.com/articles/s41467-019-11498-x). Untreated ID rapidly leads to death. However, since insulin was discovered in the early 1920s, ID has been treated with insulin therapy; an approach that converted this lethal disease into one a person can live with. Yet, insulin therapy is unsatisfactory. Indeed, ID subjects have higher risks for developing kidney failure, blindness, nerve damage, heart attack, stroke, and hypoglycemia. Some of these defects are favored by insulin therapy itself. Our goal is to diminishing the amount of insulin dosage and hence reducing the risks associated with insulin therapy (e.g. life-threatening hypoglycemia). The present application aims at providing a composition for improving the treatment of ID. If successful, we will be able to commercialize our composition and improve therapy in millions suffering from ID.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores